Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Multiple Myeloma Treatment Farydak Approved: Novartis
July 6, 2015
- Once-Weekly GLP-1 Receptor Agonist Trulicity Approved: Eli Lilly Japan
July 6, 2015
- Idiopathic Pulmonary Fibrosis Treatment OFEV Approved: NBI
July 6, 2015
- Immune Checkpoint Inhibitor Yervoy Approved for Malignant Melanoma: Bristol-Myers
July 6, 2015
- Lupus Erythematosus Treatment Plaquenil Approved: Sanofi
July 6, 2015
- Hepatitis C Treatment Harvoni Approved: Gilead Sciences
July 6, 2015
- MTPC Preparing to Submit Radicut for an Indication of ALS in the US
July 3, 2015
- Santen Files IND Application for Anti-Endoglin Antibody for Wet AMD in US
July 3, 2015
- President Tada to Double as Drug Development Head: Sumitomo Dainippon
July 3, 2015
- JCR Aims at Growth through New Products, Out-Licensing Activities
July 2, 2015
- Merck Serono, Nippon Shinyaku to Copromote Gonalef
July 2, 2015
- Announcement: 2nd Annual Oncology Asia - Sheraton Miyako Hotel Tokyo, September 7-9
July 2, 2015
- Bayer Files for Regulatory Approval of Hemophilia A Treatment in Japan
July 1, 2015
- Daiichi Sankyo Acquires Additional Shares in Kitasato Daiichi Sankyo Vaccine for 10 Billion Yen
July 1, 2015
- Febuxostat Approved for Hyperuricemia Associated with Cancer Chemotherapy in Europe: Teijin Pharma
July 1, 2015
- Taisho, Ablynx of Belgium to Collaborate for Development and Commercialization of Anti-TNF-α Nanobody
July 1, 2015
- Otsuka Initiates Voluntary Recall of Uniphyl
June 30, 2015
- Takecab Slips to 2nd Place as Suglat Comes 1st in GP Market in May: Anterio Ranking
June 30, 2015
- Bayer Obtains Approval for Eylea for Macular Edema Secondary to Retinal Vein Occlusion
June 30, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…